BridgeBio have demonstrably boosted the development of an novel treatment for ATTR-CM, utilizing Attruby. Preliminary trial data indicates significant benefits for individuals diagnosed by this debilitating disease. https://biotech169162.onzeblog.com/42319210/company-improves-cardiac-amyloidosis-therapy-with-the-drug